Home > Insider Trading > Filing (0001140361-23-051263)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1305253	Eiger Biopharmaceuticals Inc.	EIGR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
884413	A Richard Kayne	1900 Avenue Of The Stars, #1000 Los Angeles CA 90067		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-10-31	11,987	$0.26	5,108,973	No	4	P	Indirect	See footnote.
Common Stock	Acquisiton	2023-10-31	12,345	$0.26	5,121,318	No	4	P	Indirect	See footnote.
Common Stock	Acquisiton	2023-10-31	130,509	$0.24	5,251,827	No	4	P	Indirect	See footnote.
Common Stock	Acquisiton	2023-11-01	100,000	$0.28	5,351,827	No	4	P	Indirect	See footnote.
Common Stock	Acquisiton	2023-11-02	23,398	$0.30	5,375,225	No	4	P	Indirect	See footnote.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote.
No	4	P	Indirect	See footnote.
No	4	P	Indirect	See footnote.
No	4	P	Indirect	See footnote.
No	4	P	Indirect	See footnote.

Footnotes

Mr. Kayne shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Mr. Kayne and Propel General Partner act as the general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
Mr. Kayne is the trustee and beneficiary of the Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999, a California trust (the "Family Trust"), and the Family Trust acquired the referenced shares of Common Stock.
Mr. Kayne expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.